comparemela.com

Latest Breaking News On - லெய்னி கெல்லரர் - Page 7 : comparemela.com

FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device

FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device News provided by Share this article New OVD Offers Exceptional Corneal Protection, Visibility During Ophthalmic Surgery LAVAL, QC, April 7, 2021 /PRNewswire/  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health ), today announced that the U.S. Food and Drug Administration (FDA) has approved ClearVisc™ dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. The ClearVisc™ dispersive OVD is the latest advancement in Bausch + Lomb s rich pipeline of ophthalmic surgical devices and is representative of our company s ongoing commitment to delivering innovations that fulfill the unmet needs of our customers, said Joe Gordon, U.S. president, Bausch + Lomb. OVDs play a critical role in cataract surgery as well as many other ophthalmic surgeries. ClearVisc™ offers significant advantages that can help surge

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations News provided by Share this article Share this article LAVAL, Quebec, April 7, 2021 /PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company ) today announced it will reduce debt by $100 million through the redemption of outstanding senior secured notes, using cash generated from operations. Bausch Health will redeem $100 million aggregate principal amount of its outstanding 7.00% Senior Secured Notes due 2024, CUSIP Nos. 91911K AK8, C94143 AK7 (the Notes ) on May 7, 2021. The Company previously redeemed a total of $200M aggregate principal amount of the Notes in March 2021.

Bausch Health Agrees To Sell Amoun Pharmaceuticals

Bausch Health Agrees To Sell Amoun Pharmaceuticals Apr 06, 2021 2:46 PM ET Legal Newswire POWERED BY LAW.COM Bausch Health Companies Inc. announced that it and certain of its affiliates have entered into a definitive agreement to sell all of their equity interests in Amoun Pharmaceutical Company S.A.E. ( Amoun ) to Abu-Dhabi based ADQ (the Purchaser ), one of the region s largest holding companies, for total gross consideration of approximately U.S. $740 million (including the assignment to the Purchaser of an intercompany loan granted by Bausch Health to Amoun), subject to certain adjustments. As part of the transaction, cash generated by Amoun during the period from the locked-box date of January 1, 2021 to closing will be for the benefit of the Purchaser

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.